+34 93 169 65 51 info@eignapharma.com

SPOR completed one year of live service and remains the highest priority for the EMA. In this period, integrations with electronic Application Form or EudraVigilance registration system took place, and the consolidation with Art.57 and Clinical Trials was also initiated. SPOR implementation is expected to continue steadily despite EMA relocation. #SPOR #EMA

For more information, check the minutes of the task force meeting.